The estimated Net Worth of Celia Eckert is at least 3.26 百万$ dollars as of 11 March 2024. Ms. Eckert owns over 850 units of Xencor Inc stock worth over 960,675$ and over the last 5 years she sold XNCR stock worth over 279,486$. In addition, she makes 2,023,290$ as Vice President、 General Counsel、 Corporate Secretary at Xencor Inc.
Celia has made over 8 trades of the Xencor Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 850 units of XNCR stock worth 19,975$ on 11 March 2024.
The largest trade she's ever made was selling 3,892 units of Xencor Inc stock on 5 March 2024 worth over 91,190$. On average, Celia trades about 1,003 units every 110 days since 2020. As of 11 March 2024 she still owns at least 45,465 units of Xencor Inc stock.
You can see the complete history of Ms. Eckert stock trades at the bottom of the page.
Celia Eckert is Vice President, General Counsel, Corporate Secretary of the Company. Ms. Eckert has served as our General Counsel and Corporate Secretary since September 2019. Ms. Eckert oversees all legal and compliance matters for the Company, including transactions, corporate governance and intellectual property. From October 2016 to August 2019, she held roles at Synthetic Genomics, Inc., including vice president, corporate legal, where she was responsible for licensing and financial transactions, managed litigation and supported corporate legal matters. Prior to Synthetic Genomics, Ms. Eckert served as associate general counsel at Sequenom, Inc. from 2014 to October 2016, and as senior director, legal affairs at Prometheus Laboratories, Inc., which she joined in 2007. At Prometheus, she structured transactions, managed substantial patent litigation and supported the growth of the company’s commercial organization. Earlier in her career, she was an associate at Pillsbury Winthrop Shaw Pittman LLP and at Jones Day. Ms. Eckert received a B.A. in political science from the University of California, Los Angeles and a J.D. from the University of California, Hastings School of Law.
As the Vice President、 General Counsel、 Corporate Secretary of Xencor Inc, the total compensation of Celia Eckert at Xencor Inc is 2,023,290$. There are 2 executives at Xencor Inc getting paid more, with Bassil Dahiyat having the highest compensation of 3,731,510$.
Celia Eckert is 48, she's been the Vice President、 General Counsel、 Corporate Secretary of Xencor Inc since 2019. There are 16 older and 1 younger executives at Xencor Inc. The oldest executive at Xencor Inc is Richard Ranieri, 67, who is the Independent Director.
Celia's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.
Over the last 11 years, insiders at Xencor Inc have traded over 93,804,287$ worth of Xencor Inc stock and bought 1,139,502 units worth 15,515,932$ . The most active insiders traders include Capital, Llcstafford John S...、John S Iii Stafford、John S Jr Stafford. On average, Xencor Inc executives and independent directors trade stock every 23 days with the average trade being worth of 779,296$. The most recent stock trade was executed by John R Desjarlais on 9 July 2024, trading 50,000 units of XNCR stock currently worth 536,500$.
antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
Xencor Inc executives and other stock owners filed with the SEC include: